

Everyone’s panicking about the FII exodus. But here is what they are actually BUYING right now 🚨
You’ve probably seen the scary headlines: Foreign Institutional Investors (FIIs) are pulling massive amounts of money out of the Indian stock market.
Honestly, from their perspective, it makes sense. The depreciating rupee is "adding mirchi to the dal"—while the Nifty has been flat locally, the currency drop means global investors are actually sitting on a negative 9.5% return in USD terms. With India's trailing PE at a pricey 20.4 and sluggish single-digit earnings growth expected, FIIs are simply chasing better returns in the US, or riding the massive semiconductor bull runs in Taiwan and South Korea.
[Insert Image: "For global investors, Indian stock market returns are underwater"]
As a result, FIIs have been aggressively dumping traditional favorites like software companies and big banks (ICICI, HDFC, Kotak).
But here is the plot twist: they aren't abandoning India completely.
What FIIs are quietly loading up on: Instead of buying the whole index, FIIs are making highly selective, high-conviction bets on turnaround stories and niche businesses. They are buying up stocks like:
- Sammann Capital: Saw a massive 21.3% FII stake increase following a major business restructure.
- Shriram Finance: Boosted by strong rural lending growth.
- KS Smart Tech: A microcap turnaround story pivoting into IoT infrastructure.
The Domestic Advantage (What MFs are doing): While FIIs are selling, Indian Mutual Funds (MFs) are having a field day. Armed with massive, steady SIP inflows and zero distractions from other global markets, our domestic fund managers are happily buying the dip on fundamentally strong companies—like those big banks—that FIIs are panic-selling.
🔥 The "Sweet Spot" (The only 3 stocks EVERYONE is buying) 🔥 If you want to know where the truly smart money overlaps, look at the stocks both groups agree on. In the >Rs 1000 crore market cap space, there are only three stocks where both FIIs and domestic MFs increased their stakes recently:
- Marksans Pharma: A midcap pivoting to high-margin US/UK medications with great FDA approval rates and low debt.
- Natco Pharma: Using a massive cash pile from its generic cancer meds to make high-value acquisitions across emerging markets.
- Vishal Mega Mart: A hypermarket chain killing it with lower-middle-class consumers in Tier 2/3 cities through hyper-efficient capital deployment.
TL;DR: The Indian market is purely a "domestic story" right now. Don't blindly panic-sell just because FIIs are leaving the major indices. Follow the specific, high-conviction bets where both foreign and domestic money is quietly flowing